ArticleTranslational pediatrics2026
Clinical determinants of severe vaso-occlusive crisis in pediatric sickle cell anemia: a retrospective cohort study.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vaso-occlusive crisis (VOC) is the most common cause of hospitalization and morbidity among children with sickle cell anemia (SCA). Identifying clinical predictors of severe VOC may help improve early risk stratification and management. This study aimed to identify clinical determinants associated with severe VOC among pediatric patients with SCA. Methods: A retrospective observational study was conducted using hospital-based data from pediatric patients with confirmed SCA admitted with VOC in southern Saudi Arabia between August 2025 and December 2025. Severe VOC was defined using a composite outcome including severe pain, prolonged hospitalization, or intensive care unit (ICU) admission. Demographic characteristics, treatment exposures, and admission clinical parameters were analyzed. Independent predictors of severe VOC were identified using multivariable logistic regression analysis. Results: A total of 776 pediatric patients with SCA were included (mean age 9.5±3.6 years; 54.5% male). Severe VOC occurred in 385 patients (49.6%). In multivariable logistic regression analysis (n=596), higher admission temperature [adjusted odds ratio (aOR) 1.69, 95% confidence interval (CI): 1.34-2.15, P<0.001] and increased annual blood transfusion frequency (aOR 1.28, 95% CI: 1.16-1.40, P<0.001) were independently associated with severe VOC. Hydroxyurea therapy demonstrated a protective effect, reducing the risk of severe crisis by approximately 42% (aOR 0.58, 95% CI: 0.43-0.78, P<0.001). The predictive model showed modest but statistically significant discrimination (AUC 0.626, 95% CI: 0.587-0.665, P<0.001). Conclusions: Severe VOC in children with SCA appears to be primarily associated with acute inflammatory triggers, particularly elevated admission temperature, and markers of underlying disease severity such as frequent transfusion requirements. Hydroxyurea therapy demonstrated a significant protective effect, supporting its role in reducing the risk of severe VOC complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.